Acorda Therapeutics, Inc.
ACORQ
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 87.42% | -2,350.06% | 5.26% | 44.24% | -187.89% |
| Total Depreciation and Amortization | -88.87% | 0.08% | 0.05% | 0.00% | -1.57% |
| Total Amortization of Deferred Charges | 4.53% | 4.53% | 4.52% | 4.55% | -2.23% |
| Total Other Non-Cash Items | -96.98% | 3,556.98% | -126.32% | 11.90% | 85.12% |
| Change in Net Operating Assets | 40.63% | -192.40% | 181.22% | -2,581.89% | 122.78% |
| Cash from Operations | -568.82% | -139.67% | 165.84% | -64.66% | -177.41% |
| Capital Expenditure | -- | 80.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 80.00% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -200.00% | 159.24% | -201.29% | 59.79% | -92.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -582.99% | -141.06% | 163.42% | -64.73% | -165.96% |
